Trial Profile
A Phase 2 Multicenter Study of CNTO 328 (Anti IL [interleukin]-6 Monoclonal Antibody) in Subjects with Relapsed or Refractory Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Siltuximab (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 03 Mar 2010 Status changed from active, no longer recruiting to completed.
- 21 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
- 06 Oct 2009 Planned end date changed from 1 Feb 2009 to 1 Apr 2011 as reported by ClinicalTrials.gov.